{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '240 East Grand Avenue',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 22.11,
 'askSize': 800,
 'averageDailyVolume10Day': 189712,
 'averageVolume': 234839,
 'averageVolume10days': 189712,
 'beta': None,
 'beta3Year': None,
 'bid': 22.07,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.48,
 'dayLow': 21.8501,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -25.011,
 'enterpriseToRevenue': None,
 'enterpriseValue': 759473152,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 30.344572,
 'fiftyTwoWeekHigh': 40.67,
 'fiftyTwoWeekLow': 21.85,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16210138,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 57,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01471,
 'heldPercentInstitutions': 0.45087,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/oricpharma.com',
 'longBusinessSummary': 'ORIC Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, discovers and develops '
                        'therapies for treatment of cancers. Its lead product '
                        'candidate is ORIC-101, a small molecule antagonist of '
                        'the glucocorticoid receptor, which has been linked to '
                        'resistance to multiple classes of cancer therapeutics '
                        "across various solid tumors. The company's second "
                        'product candidate is ORIC-533, an orally bioavailable '
                        'small molecule inhibitor of CD73 being developed for '
                        'resistance to chemotherapy- and immunotherapy-based '
                        'treatment regimens. It is also developing multiple '
                        'precision medicines targeting other cancer resistance '
                        'mechanisms. The company was founded in 2014 and is '
                        'headquartered in South San Francisco, California.',
 'longName': 'ORIC Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 660856320,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_303713108',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -29740000,
 'nextFiscalYearEnd': 1640908800,
 'open': 23.39,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-388-5600',
 'previousClose': 23.55,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.48,
 'regularMarketDayLow': 21.8501,
 'regularMarketOpen': 23.39,
 'regularMarketPreviousClose': 23.55,
 'regularMarketPrice': 23.39,
 'regularMarketVolume': 109661,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 29903000,
 'sharesPercentSharesOut': 0.0838,
 'sharesShort': 2506836,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1687809,
 'shortName': 'Oric Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1381,
 'shortRatio': 9.24,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ORIC',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 30.210155,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'dc096b5b-6f44-3289-9c72-d0a4b5607b05',
 'volume': 109661,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.oricpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}